Development of Second Messenger, Trafficking, and Functional Assays for GPR119

GPR119 第二信使的开发、贩运和功能分析

基本信息

批准号：
8249918
负责人：
Patricia Helen McDonald
金额：
$ 41.12万
依托单位：
SCRIPPS RESEARCH INSTITUTE, THE
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-04-05 至 2014-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8249918
关键词：
Address Agonist Animal Model Biological Assay Biology Biosensor Brain CNR2 gene Cell Line Cells Chemicals Collection Complement 3 Coupled Cyclic AMP Detection Developing Countries Development Diabetes Mellitus Discrimination Disease Dyes Eating Enzymes G Protein-Coupled Receptor Genes G-Protein-Coupled Receptors GCG gene GTP-Binding Proteins Gastrointestinal tract structure Generations Goals Human Image In Vitro Insulin Intestines L Cells Life Ligands Literature Measurement Measures Mediating Membrane Potentials Metabolic Diseases Molecular Probes Monitor Morphologic artifacts Non-Insulin-Dependent Diabetes Mellitus Obesity Pancreas Pharmacology Physiological Physiological Processes Prevalence Property Rattus Reader Receptor Activation Reporting Rodent Screening procedure Second Messenger Systems Series Signal Transduction Societies Structure of beta Cell of islet Technology Triage Weight Gain Work base blood glucose regulation cardiovascular disorder risk cell type counterscreen cyclic-nucleotide gated ion channels design high throughput screening improved innovation insulin secretion novel obesity treatment oleoylethanolamide overexpression public health relevance receptor receptor function second messenger small molecule therapeutic target trafficking

项目摘要

DESCRIPTION (provided by applicant): The G protein coupled receptor GPR119 is a recently deophanized receptor that has emerged as an attractive target for the treatment of obesity and Type 2 Diabetes Mellitus. Recent studies in animal models have demonstrated that activation of GPR119 improves glucose homeostasis while positively modulating both food intake and weight gain. It is expressed predominantly in the pancreas and gut of humans and rats and in rodent brain. Activation of GPR119 promotes secretion of the incretin GLP1 from intestinal L cells and insulin from pancreatic beta cells, both key components in regulating glucose homeostasis. Small molecule modulators of GPR119 have recently been reported however, these molecules differ with respect to their signaling properties and insulin secretion from the endogenous ligand Olethylethanolamide (OEA), rendering them unsuitable probes for the interrogation of GPR119 biology and function. The emphasis of this application is on developing innovative and novel assays for GPR119 that are HTS compatible, secondary screening assays to triage artifacts, counterscreens to assess selectivity of compounds versus two structurally related GPCRs and functional assays to elucidate pharmacology of compounds in physiologically relevant cell types to assess in vitro efficacy for promoting incretin and insulin secretion. These assays are designed to be the cornerstone for the discovery of novel small molecule probes to be used in the exploration of GPR119 biology and function. PUBLIC HEALTH RELEVANCE: The GPR119 receptor is expressed in the pancreas and gastrointestinal tract and has recently emerged as an attractive target for the treatment of obesity and Type 2 Diabetes Mellitus. This proposal seeks to develop a series of novel high throughput compatible cell-based functional assay to identify GPR119 selective ligands that can be used as molecular probes to interrogate GPR119 receptor function in normal physiological processes and disease states.

描述（由申请人提供）：G蛋白偶联受体GPR119是一种最近去灭绝的受体，已成为治疗肥胖症和2型糖尿病的有吸引力的靶标。动物模型中的最新研究表明，GPR119的激活可改善葡萄糖稳态，同时对食物摄入和体重增加。它主要在人类和大鼠的胰腺和肠道以及啮齿动物的大脑中表达。 GPR119的激活促进了从肠道L细胞和胰岛β细胞中胰岛素的分泌，这都是调节葡萄糖稳态的关键成分。最近已经报道了GPR119的小分子调节剂，这些分子在其信号传导特性和与内源性配体少甲基乙醇酰胺（OEA）的胰岛素分泌方面有所不同，使它们不合适地探测GPR119生物学和功能。 The emphasis of this application is on developing innovative and novel assays for GPR119 that are HTS compatible, secondary screening assays to triage artifacts, counterscreens to assess selectivity of compounds versus two structurally related GPCRs and functional assays to elucidate pharmacology of compounds in physiologically relevant cell types to assess in vitro efficacy for promoting incretin and insulin secretion.这些测定旨在发现用于探索GPR119生物学和功能的新型小分子探针的基石。公共卫生相关性：GPR119受体在胰腺和胃肠道中表达，最近已成为治疗肥胖症和2型糖尿病的有吸引力的靶标。该提案旨在开发一系列新型的高吞吐量基于细胞的功能测定，以识别GPR119的选择性配体，这些配体可以用作分子探针，以在正常的生理过程和疾病状态中询问GPR119受体功能。